Relative bioavailability and safety of aripiprazole lauroxil, a novel once-monthly, long-acting injectable atypical antipsychotic, following deltoid and gluteal administration in adult subjects with schizophrenia - Turncliff, Ryan; Hard, Marjie; Du, Yangchun; Risinger, Robert; Ehrich, Elliot W. (Schizophrenia research, 2014)
Keywords: Adult; Adult and adolescent clinical studies; Antipsychotic Agents - administration & dosage; Antipsychotic Agents - adverse effects; Antipsychotic Agents - pharmacokinetics; Aripiprazole; Aripiprazole lauroxil; Atypical antipsychotic; Biological and medical sciences; Biological Availability; Buttocks; Delayed-Action Preparations; Deltoid; Deltoid Muscle - drug effects; Female; Gluteal; Humans; Injections, Intramuscular; Long-acting injectable; Male; Medical sciences; Middle Aged; Neuropharmacology; Pharmacology. Drug treatments; Piperazines - administration & dosage; Piperazines - adverse effects; Piperazines - pharmacokinetics; Psychiatry; Psycholeptics: tranquillizer, neuroleptic; Psychology. Psychoanalysis. Psychiatry; Psychopathology. Psychiatry; Psychopharmacology; Psychoses; Quinolones - administration & dosage; Quinolones - adverse effects; Quinolones - pharmacokinetics; Schizophrenia; Schizophrenia - drug therapy; Young Adult; Gluteal; Aripiprazole lauroxil; Atypical antipsychotic; Deltoid; Schizophrenia; Long-acting injectable; Aripiprazole; Human; 5-HT2A serotonin receptor; Partial agonist; Controlled release form; Neuroleptic; Psychotropic; Quinolinone derivatives; Bioavailability; Psychosis; D2 Dopamine receptor; 5-HT1A Serotonine receptor; Dosage form; Adult; Antagonist; Safety